logo
Share SHARE
FONT-SIZE Plus   Neg

Regeneron Pharma To Get Addl. Potential Royalty Stream On EU Approval For Ilaris

Regeneron Pharmaceuticals Inc. (REGN) said it would receive an additional potential royalty stream now that the European Commission or EC has approved Novartis' llaris in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with current treatment options. Ilaris, a registered trademark of Novartis, is the first biologic approved in the European Union or EU for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection of 150 mg.1

As part of June 2009 agreement with Novartis, Regeneron receives royalties on worldwide sales of Ilaris. The overall royalty rate in the agreement starts at 4% and reaches 15% when annual sales exceed $1.5 billion. In 2012, Regeneron posted annual Ilaris royalties of $2.8 million.

In the EU, Ilaris is specifically indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks in whom non-steroidal anti-inflammatory drugs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
General Motors' Chevrolet, the first automotive brand to add 4G LTE connectivity across its entire vehicle portfolio, has now slashed its OnStar 4G LTE data plan pricing by up to 50 percent ahead of the upcoming 2016 Independence Day, the company said in a statement. Shares of Tractor Supply Co. (TSCO) slipped over 7 percent in the extended hours after the company issued a weak second-quarter guidance and lowered its annual outlook, due to weak sales of its seasonal products. For the second quarter, the company now expects earnings of $1.15 to $1.16 per share... Hard-disk driver maker Seagate Technology plc (STX) late Wednesday said it was cutting 1,600 jobs or about 3% of its global workforce to curb expenses. The company expects to save about $100 million a year, having a favorable impact on cost of revenue and operating expenses by about $48 million and...
comments powered by Disqus
Follow RTT